Alx oncology appoints board member barbara klencke, m.d., as interim chief medical officer

South san francisco, calif., sept. 12, 2025 (globe newswire) -- alx oncology holdings inc., (“alx oncology” or “the company”) (nasdaq: alxo), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced the appointment of dr. klencke to the role of interim chief medical officer (cmo) on a full-time basis. dr. alan sandler is departing from the role of cmo and will return to his former position on the alx oncology board of directors (bod), where he previously served.
ALXO Ratings Summary
ALXO Quant Ranking